John Bostock. Novel Immunotherapy Modalities. Catharrus aestivus. University Hospital Zürich. Thomas M. Kündig Dermatology Zurich University Hospital
|
|
- Nathan McCarthy
- 5 years ago
- Views:
Transcription
1 John Bostock University Hospital Zürich Novel Immunotherapy Modalities 1819 Catharrus aestivus Thomas M. Kündig Dermatology Zurich University Hospital
2 Charles Blackley William Dunbar 1873 Catarrhus aestivus 1903 Pollantin caused by pollen
3 John Freeman and Leonard Noon Lancet 1911
4 Allergen Immunotherapy High rate of success Insect venoms 80-95% Pollen 70-80% Tolerance dose Only causal treatment Stops progression of disease Long term effect As effective as pharmacotherapy
5 Subcutaneous Immunotherapy SLIT Only 4% Time consuming Allergic side effects Allergen dose 20 weeks 3-5 years (30-80 injections) Senna et al. JACI 2010
6 Understanding of Immunology von Behring Shibasaburo humoral theory Allergens = toxins Ehrlich antibody formation theory Allergies caused by IgE Gershon suppressor T cells Mosmann Coffman Th1 / Th2 Sakaguchi Treg What is the mechanism? Dunbar passive vaccination Noon / Freeman active vaccination Vaccination Cooke blocking antibodies Rocklin SIT induces suppressor T cells Varney SIT induces Th1 Akdis T cell tolerance Tolerance induction Bellinghausen SIT induces T reg Interpretation of SIT
7 Blocking Antibodies Understanding of Immunology Allergens = toxins Allergies caused by IgE von Behring Shibasaburo humoral theory Ehrlich antibody formation theory Ishizaka Johansson IgE Gershon suppressor T cells Mosmann Coffman Th1 / Th2 Sakaguchi Treg Dunbar passive vaccination Noon / Freeman active vaccination Vaccination Cooke blocking antibodies Rocklin SIT induces suppressor T cells Varney SIT induces Th1 Akdis T cell tolerance Tolerance induction Bellinghausen SIT induces T reg Cook JEM 1935 Interpretation of SIT
8 Dose Dependence How can this be improved? Symptoms Placebo Medium dose High dose UK Immunotherapy Study Group JACI 2006
9 Anti-PLA2 IgG2a Allergen Administration Route 0.01 µg 0.1 µg 10 µg intralymphatic (ILIT) subcutaneous (SCIT) intraperitoneal IFNg secretion (pg/ml) IL SC IL-4 secretion (pg/ml) IFNγ IL IL SC IL-2 secretion (pg/ml) IL-10 secretion (pg/ml) IL-2 IL SC IL-10 IL SC Matinez-Gómez et al. Int Arch Allergy Immunol 2009 Matinez-Gómez et al. Int Arch Allergy Immunol 2009
10 0.8 Adjuvants CpG dose (nmol) 10 nmole nmole nmole nmole into lymph node Subcutaneous i.ln. s.c. IgG2a (OD 405 nm) Anti-PLA 2 IgG2a (OD 405 nm) i.ln. s.c Serum dilution von Beust et al Eur J Immunol 2005
11 25 h Inguinal Lymph Nodes no large vessels little movement close to vessels leg movement Senti et al. Curr Opin Allergy Clin Immunol 2009
12 Intralymphatic Injection Pain? Pain score (VAS) Intralymphatic injection Venous puncture Senti et al. PNAS 2008
13 165 grass allergic pat treatment Patients 8 Senti et al. PNAS Allergen (SQ-U) Allergen (SQ-U) Cum. dose = SQ-U Pollen season baseline Cum. dose = SQ-U Pollen Pollen weeks season season baseline 4 months 1 year 3 years Evaluation Sept Jan Sept Sept visits Oct Feb Oct Oct B Maximum tolerated concentration (log10) Nasal Provocation Test intralymphatic subcutaneous Months Senti et al. PNAS 2008
14 Reproducible Hyalnder et al. JACI 2013
15 Antigen Presentation CAST-ELISA allergen IhC Fel d endolysosome allergen Tat Lysosom YYY slt (pg/ml) IhC MAT-Fel d 1 rfel d 1 Cat extract Golgi Golgi 500 Tat ER invariant chain (Ii) MHCII MHCII ER Leukotriens Fel d 1 Concentration (nm) Matinez-Gómez et al. Allergy 2009
16 Skin Prick Test MAT Fel d 1 IVN-CAT-001b 12 Alum + MAT-Fel d 1 Threshold concentration Cat hair extract P value IVN201 Cat hair extract MAT-Fel d 1 93x 8 Alum + placebo 1 µg 3 µg 10 µg 5d 28d 28d 28d V1a V1b V2a V2b V2c V3 V4 Screening Treatment Efficacy
17 IgG4 IL-10 a Titer (Post/Pre) 100 IgG4 10 p<0.05 ** Placebo Verum IL-10 (pg/ml) Placebo Verum p<0.05 p=n.s. Pre Post Pre Post
18 IL-10 Correlates with IgG4 Nasal Tolerance 100 p= p=n.s. 3 IgG4 (Post/Pre) 10 1 Improvement (Post/Pre log 1 0 ) 2 1 P< x IL-10 (Post/Pre) 0 Placebo Verum
19 ILIT vs. SCIT Low allergen doses Improved safety Enhanced immunogenicity Fewer injections Practically painless Enhanced compliance
20 Dogs with Atopic Dermatitis Horse Asthma 3 x ILIT better than 30 x s.c. Hatzmann et al. Vet Dermatol 2011
21 Horse Asthma
22 Antibodies of all four isotypes, IgG 1, IgG 2, IgA, and IgM, increased in dry secretions following immunization via lymph node.
23 J Immunother 2008
24 Epicutaneous Immunotherapy (EPIT) Blamoutier 1959
25
Intralymphatic Immunotherapy ILIT. Gabriela Senti Center for Clinical Research University and University Hospital Zurich
Intralymphatic Immunotherapy ILIT Gabriela Senti Center for Clinical Research University and University Hospital Zurich Subcutaneous Immunotherapy Problems Intralymphatic Immunotherapy Protein Vaccines
More informationMechanisms of allergen-specific immunotherapy
2012 KAAACI/EAAS Spring Mechanisms of allergen-specific immunotherapy Woo-Jung Song, MD Division of Allergy and Clinical Immunology Department of Internal Medicine Seoul National University Hospital, Seoul,
More informationMechanismen der allergenspezifischen Immuntherapie
Mechanismen der allergenspezifischen Immuntherapie Medizinische Universität Wien Zentrum für Pathophysiologie, Infektiologie und Immunologie Institut für Pathophysiologie und Allergieforschung Abteilung
More informationNew Approaches to Immunotherapy: Beyond SCIT and SLIT
New Approaches to Immunotherapy: Beyond SCIT and SLIT Harold S. Nelson, MD Professor of Medicine National Jewish Health and University of Colorado Denver School of Medicine Denver, Colorado Disclosure:
More informationSLIT: Review and Update
SLIT: Review and Update Disclosure Speaker: ISTA Pharmaceuticals Speaker: GlaxoSmithKline Allergen IT - Evidence Based Evaluation: Rescue Medications Meta-analysis Disease IT # of Patients Rescue Medication
More informationallergy Asia Pacific Allergen-specific intralymphatic immunotherapy in human and animal studies Current Review INTRODUCTION
pissn 2233-8276 eissn 2233-8268 Current Review Asia Pac Allergy 2017;7:131-137 Allergen-specific intralymphatic immunotherapy in human and animal studies Seon Tae Kim 1,, So Hyun Park 2,, Sang Min Lee
More informationPractical Course Allergen Immunotherapy (AIT) How to be effective. Michel Dracoulakis HSPE- FMO São Paulo-SP Brazil
Practical Course Allergen Immunotherapy (AIT) How to be effective Michel Dracoulakis HSPE- FMO São Paulo-SP Brazil Allergen immunotherapy - beginning Dunbar almost died with first inoculation 1911 Noon
More informationRECOMMENDATIONS FOR APPROPRIATE SLIT TRIALS
RECOMMENDATIONS FOR APPROPRIATE SLIT TRIALS Giovanni Passalacqua Allergy & Respiratory Diseases Dept.Internal MedicineIRCCS S.Martino IST University of Genoa ITALY CHICAGO-WAO-2013 ISHIZAKA NOON UK CSM
More informationIntroduction. Methods. Results 12/7/2012. Immunotherapy in the Pediatric Population
12/7/212 Introduction Immunotherapy in the Pediatric Population Michael S. Blaiss, MD Clinical Professor of Pediatrics and Medicine University of Tennessee Health Science Center Memphis, Tennessee Allergen
More informationExpert Roundtable on Sublingual Immunotherapy
Expert Roundtable on Sublingual Immunotherapy FACULTY Linda Cox, MD Clinical Associate Professor, Nova Southeastern University Thomas Casale, MD Professor of Medicine, University of South Florida Peter
More informationALK-Abelló Research & Development. Henrik Jacobi MD, EVP Research & Development
ALK-Abelló Research & Development Henrik Jacobi MD, EVP Research & Development Agenda Latest news on GRAZAX 3rd year data from long-term study (GT-08) Effect on asthma symptoms in children (GT-12) Status:
More informationINVESTIGATIONS & PROCEDURES IN PULMONOLOGY. Immunotherapy in Asthma Dr. Zia Hashim
INVESTIGATIONS & PROCEDURES IN PULMONOLOGY Immunotherapy in Asthma Dr. Zia Hashim Definition Involves Administration of gradually increasing quantities of specific allergens to patients with IgE-mediated
More informationReview on immunotherapy in airway allergen sensitised patients
REVIEW Review on immunotherapy in airway allergen sensitised patients J.P.M van der Valk*, N.W. de Jong, R. Gerth van Wijk Department of Internal Medicine, section of Allergology, Erasmus MC, Rotterdam,
More informationAllergen Immunotherapy in Asthma: Now and in the Future
Allergen Immunotherapy in Asthma: Now and in the Future Young-Il Koh, M.D. Chonnam National University Medical School, Gwangju, Korea 2017-03-25 CHONNAM NATIONAL UNIVERSITY MEDICAL SCHOOL 1 Management
More informationNew Approaches to Immunotherapy
New Approaches to Immunotherapy Harold S. Nelson, MD Professor of Medicine National Jewish Health and University of Colorado School of Medicine, Denver, Colorado, USA Faculty Disclosure Harold S. Nelson,
More informationAEROALLERGEN IMMUNOTHERAPY FOR ALLERGIC RHINITIS
AEROALLERGEN IMMUNOTHERAPY FOR ALLERGIC RHINITIS Persia Pourshahnazari MD, FRCPC Clinical Immunology and Allergy November 4, 2018 OBJECTIVES Review indications and evidence for aeroallergen immunotherapy
More informationNew Frontiers in Allergen Immunotherapy
New Frontiers in Allergen Immunotherapy Bryan Martin, DO, MMAS, FACP. FACOI, FAAAI, DFACAAI President, The American College of Allergy, Asthma & Immunology Emeritus Professor of Medicine and Pediatrics
More informationThe European Academy of Allergy & Clinical Immunology s Allergen Immunotherapy Guidelines
The European Academy of Allergy & Clinical Immunology s Allergen Immunotherapy Guidelines Professor Aziz Sheikh OBE BSc, MSc, MD, FRCGP, FRCP, FRCPE, FFPH, FACMI, FRSE, FFCI, FMedSci Director, Usher Institute
More informationBy the end of this lecture physicians will:
No disclosure By the end of this lecture physicians will: 1. Be able to identify patients who need immune work-up. 2. Be able to recognize the manifestation of food allergies. 3. Be knowledgeable about
More informationIntralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial
Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial Gabriela Senti a, b, Bettina M. Prinz Vavricka a, Iris Erdmann a, Mella I. Diaz c,
More informationIMMUNOTHERAPY IN ALLERGIC RHINITIS
Rhinology research Chair Weekly Activity, King Saud University IMMUNOTHERAPY IN ALLERGIC RHINITIS E V I D E N C E D - B A S E O V E R V I E W O F T H E R U L E O F I M M U N O T H E R A P Y I N A L L E
More informationThe Future of Allergy Treatment Ultra-Fast Allergy Immunotherapy
The Future of Allergy Treatment Ultra-Fast Allergy Immunotherapy 1 Anergis Focus on Allergy Immunotherapy (AIT) High Medical Need and Patient Demand 500 M allergic patients - fastest growing chronic condition
More informationAllergens And Allergen Immunotherapy Fourth Edition Clinical Allergy And Immunology
Allergens And Allergen Immunotherapy Fourth Edition Clinical Allergy And Immunology 1 / 6 2 / 6 3 / 6 Allergens And Allergen Immunotherapy Fourth areas of allergens and immunotherapies: pollens animal/insect
More informationMechanisms of Allergen-specific immunotherapy
relative change relative change Mechanisms of Allergen-specific immunotherapy Cezmi A. Akdis Swiss Institute of Allergy and Asthma Research (SIAF) mechanisms of SIT. Basophil, mast cell desensitisation,
More informationCenters. Austria (2), Germany (5), Belgium (1), Netherlands (1), Denmark (1), Slovenia (1)
Study CS-BM32-003 Sponsor Biomay Protocol title Phase IIb study on the safety and efficacy of BM32, a recombinant hypoallergenic vaccine for immunotherapy of grass pollen allergy Clinical trial phase Phase
More informationAllergic Rhinitis and Its Impact on Ast. Rhinitis: A Risk Factor for Asthma? Ronald Dahl, Aarhus University Hospital, Denmark
Allergic Rhinitis and Its Impact on Ast Rhinitis: A Risk Factor for Asthma? Ronald Dahl, Aarhus University Hospital, Denmark Rhinitis and asthma SIT-SLIT Evidence A SIT-SLIT Evidence A? SIT Evidence? Rhinitis
More informationAllergen Immunotherapy: An Update
Allergen Immunotherapy: An Update Susan Waserman MSc MDCM FRCPC Professor of Medicine Division of Clinical Allergy and Immunology CTS Calgary April 26, 2014 Presenter Disclosure Presenter: Dr Susan Waserman
More informationUse of SLIT in allergy practice: Is it ready for prime time? Stanley Fineman, MD, MBA Atlanta Allergy & Asthma Clinic AAIFNC, Feb 7, 2015
Use of SLIT in allergy practice: Is it ready for prime time? Stanley Fineman, MD, MBA Atlanta Allergy & Asthma Clinic AAIFNC, Feb 7, 2015 Disclosures Speakers bureau/consultant: AZ, Genentech/Novartis,
More informationCurrent and Future Prospects for the Treatment of Food Allergy
Current and Future Prospects for the Treatment of Food Allergy Robert A. Wood, MD Professor of Pediatrics and International Health Director, Pediatric Allergy and Immunology Director, Pediatric Clinical
More informationMouse Anti-HDM IgG Antibody Assay Kit
Mouse Anti-HDM IgG Antibody Assay Kit Catalog # 3030 For Research Use Only - Not Human or Therapeutic Use INTRODUCTION Asthma is a common chronic inflammatory disease that affects 300 million people of
More informationNew Directions in Immunotherapy: Accelerated Schedules and Routes for Immunotherapy. Linda Cox, MD
New Directions in Immunotherapy: Accelerated Schedules and Routes for Immunotherapy Linda Cox, MD Disclosures for Linda Cox, MD For the 12 months preceding this CME activity, I or my spouse/partner disclose
More informationATOPY. Allergic immune response. ??? an imbalance between Th1 and Th2. Burden of allergic disorders increase. routes
Burden of allergic disorders increase An immunological overview of allergen specific immunotherapysubcutaneous&sublingual routes Asthma Allergic Rhinitis Atopic Dermatitis Urticaria&Angioedema Food, Latex,
More informationTherapies for allergic inflammation: refining strategies to induce tolerance
f o c u s o n A ST H M A Therapies for allergic inflammation: refining strategies to induce tolerance Cezmi A Akdis Current therapies for asthma and allergy are relatively safe and effective at controlling
More informationNutricia Paediatric Allergy Symposium 24 th May 2016
Nutricia Paediatric Allergy Symposium 24 th May 2016 The speaker had sole editorial control over the content in this slide deck. Any views, opinions or recommendations expressed in the slides are solely
More informationMouse Serum Anti-HDM IgE Antibody Assay Kit
Mouse Serum Anti-HDM IgE Antibody Assay Kit Catalog # 3037 For Research Use Only - Not Human or Therapeutic Use INTRODUCTION Asthma is a common chronic inflammatory disease that affects 300 million people
More informationP O S S I B L E A N A P H Y L A X I S T O M O S Q U I T O B I T E
P O S S I B L E A N A P H Y L A X I S T O M O S Q U I T O B I T E S E A R C H A G A I N Q: 8/25/2014 8 month old female had an allergic reaction to mosquito which possibly caused anaphylaxis. She had hives
More informationMouse Anti-OVA IgM Antibody Assay Kit
Mouse Anti-OVA IgM Antibody Assay Kit Catalog # 3017 For Research Use Only - Not Human or Therapeutic Use INTRODUCTION Ovalbumin (OVA) is a widely used antigen for inducing allergic reactions in experimental
More informationWhat are Allergy shots / SCIT?
Allergy diagnosis must be made accurately with correct history and tests including the skin prick test and the blood test like immunocap / Phadiatop study. This once made will help decide the dose and
More informatione. Elm Correct Question 2 Which preservative/adjuvant has the greatest potential to breakdown immunotherapy because of protease activity? a.
Allergen Immunotherapy Practical Quiz Question 1 Which of the following pollens shows cross-reactivity with birch pollen? a. Alder b. Olive c. Ash d. Black walnut e. Elm Question 2 Which preservative/adjuvant
More informationCan dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience
L E T T ER T O T H E E D I T O R Eur Ann Allergy Clin Immunol Vol 49, N 2, 92-96, 2017 G. Liccardi 1,2, L. Calzetta 2,3, A. Salzillo 1, L. Billeri 4, G. Lucà 3, P. Rogliani 2,3 Can dog allergen immunotherapy
More informationHow close are we to predicting allergenicity of new proteins? 13 April 2012, Praha Corinne Herouet-Guicheney, PhD
How close are we to predicting allergenicity of new proteins? 13 April 2012, Praha Corinne Herouet-Guicheney, PhD Agenda/ Content Potential risk and basic principles Current status in developing a model
More informationAssociate Professor Rohan Ameratunga Immunologist & Allergist, Auckland
Associate Professor Rohan Ameratunga Immunologist & Allergist, Auckland Update on desensitisation Associate Professor Rohan Ameratunga GLORIA Module 4: Allergen Specific Immunotherapy A New Zealand perspective
More informationAllergies & Hypersensitivies
Allergies & Hypersensitivies Type I Hypersensitivity: Immediate Hypersensitivity Mediated by IgE and mast cells Reactions: Allergic rhinitis (hay fever) Pollens (ragweed, trees, grasses), dust mite feces
More informationImproving allergy outcomes. Allergen Component Testing. Jay Weiss Ph.D and Gary Kitos, Ph.D. H.C.L.D.
Improving allergy outcomes Allergen Component Testing Jay Weiss Ph.D and Gary Kitos, Ph.D. H.C.L.D. Allergen Component Testing Allergic disease is an immunologic response to an allergen or allergens that
More informationThree-year Short-term Specific Immunotherapy (SIT): A Multi-centre, Double-blind Placebo-controlled Study with L-tyrosine adsorbed Pollen Allergoids
Three-year Short-term Specific Immunotherapy (SIT): A Multi-centre, Double-blind Placebo-controlled Study with L-tyrosine adsorbed Pollen Allergoids Introduction KJ Drachenberg, U Feeser, and P Pfeiffer
More informationSensitivity to Sorghum Vulgare (Jowar) Pollens in Allergic Bronchial Asthma and Effect of Allergen Specific Immunotherapy
Indian J Allergy Asthma Immunol 2002; 16(1) : 41-45 Sensitivity to Sorghum Vulgare (Jowar) Pollens in Allergic Bronchial Asthma and Effect of Allergen Specific Immunotherapy Sanjay S. Pawar Shriratna Intensive
More informationWest Houston Allergy & Asthma, P.A.
Consent to Receive Immunotherapy (ALLERGY SHOTS) Procedure Allergy injections are usually started at a very low dose. This dose is gradually increased on a regular (usually 1-2 times per week) basis until
More informationSecondary prevention of allergic disease. Dr Adam Fox United Kingdom
Secondary prevention of allergic disease Dr Adam Fox United Kingdom Disclosures Lecture fees: Danone, Mead Johnson, ALK-Abello, Stallergenes, Allergy Therapeutics Industry-sponsored grant: Danone, ALK-Abello
More informationAllergen-Specific Immunotherapy: Hocus Pocus or Legitimate Therapy Holly Roberts, DVM, MS, DACVD
Allergen-Specific Immunotherapy: Hocus Pocus or Legitimate Therapy Holly Roberts, DVM, MS, DACVD 1. Allergic Disease a. Atopic Dermatitis i. Seasonal ii. Nonseasonal iii. Seasonally nonseasonal b. Cutaneous
More informationimmunotherapy to parietaria. A controlled field study
O R I G I N A L A R T I C L E Eur Ann Allergy Clin Immunol VOL 42, N 3, 115-119, 2010 A. Musarra 1, D. Bignardi 2, C. Troise 2, G. Passalacqua 3 Long-lasting effect of a monophosphoryl lipidadjuvanted
More informationNew Horizons Session on Specific Immunotherapy (SIT) Session 4: Practical considerations for SIT. When should SIT be started and why?
New Horizons Session on Specific Immunotherapy (SIT) Session 4: Practical considerations for SIT When should SIT be started and why? Lars Jacobsen: Research Centre for Prevention and Health Glostrup University
More informationPollen immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis (The PAT-Study)
Pollen immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis (The PAT-Study) Christian Möller 1, Sten Dreborg 2, Hosne A. Ferdousi 3, Susanne Halken 4, Arne Høst
More informationFood Allergy. Wesley Burks, M.D. Curnen Distinguished Professor and Chair Department of Pediatrics University of North Carolina
Food Allergy Wesley Burks, M.D. Curnen Distinguished Professor and Chair Department of Pediatrics University of North Carolina Faculty disclosure FINANCIAL INTERESTS I have disclosed below information
More informationJean-Michel Wal, Karine Adel-Patient, Herve Bernard and Stephane Hazebrouck
The BALB/c mouse model of allergy for the assessment of sensitizing properties of proteins and foods and their alteration by environmental conditions Jean-Michel Wal, Karine Adel-Patient, Herve Bernard
More informationHow immunology informs the design of immunotherapeutics.
How immunology informs the design of immunotherapeutics. Stephen R Durham Allergy and Clinical Immunology, Royal Brompton Hospital and Imperial College London WAO Cancun Mon Dec 5 th 2011 How immunology
More informationCuring Allergy. Characteristics of products for specific allergy management. Jorgen Nedergaard Larsen, PhD. Senior scientist. dk.alk-abello.
Characteristics of products for specific allergy management Jorgen Nedergaard Larsen, PhD Senior scientist jnl @ dk.alk-abello.com 11 May 2012 Introduction to ALK-Abelló Pharmaceutical company devoted
More informationAllergen immunotherapy: from EBM to doctors and patients need
Allergen immunotherapy: from EBM to doctors and patients need Moscow, Marriott Hotel February 28th, 2019 Dr. Franco Frati Medical Department Milan, Italy From the recognition of the pollen to in vivo tests
More informationFormat. Allergic Rhinitis Optimising Mananagement. Degree of Quality of life Restriction in the Allergic Patient. The allergy epidemic:
Format Allergic Rhinitis Optimising Mananagement Dr Dominic Mallon FRACP FRCPA Clinical Immunologist and Allergist Fiona Stanley Hospital Impact of allergic rhinitis Diagnosis and management of allergic
More informationDefinition of Allergens 2013 Is there a need for Seasonal & Perennial?
MANIFESTO Definition of Allergens 2013 Is there a need for Seasonal & Perennial? Canonica G.W. Baena Cagnani C.E. Bousquet J. Pawankar R. Zuberbier T. Reasons for NOT using the classification of SEASONAL
More informationALLERGY TESTING AND TREATMENT
Status Active Medical and Behavioral Health Policy Section: Laboratory Policy Number: VI-02 Effective Date: 03/26/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More informationAllergen Immunotherapy
Allergen Immunotherapy ASCIA EDUCATION RESOURCES (AER) PATIENT INFORMATION Allergen immunotherapy switches off allergy Although medications available for allergy are usually very effective, they do not
More informationIs Early Exposure to Allergens Protective? Adnan Custovic MSc DM MD PhD Professor of Allergy North West Lung Centre Manchester, UK
Is Early Exposure to Allergens Protective? Adnan Custovic MSc DM MD PhD Professor of Allergy North West Lung Centre Manchester, UK Highest Sensitisation Rate With Moderate Dose Antigen Exposure Anti-KLH
More informationCanine Atopic Dermatitis & Immunotherapy
STEP 1: Comprehensive Overview Canine Atopic Dermatitis & Immunotherapy Jennifer Schissler Pendergraft, DVM, MS, DACVD Colorado State University Canine atopic dermatitis (CAD), one of the most common diagnoses
More informationSUBLINGUAL IMMUNOTHERAPY: What is the role in mucosal tolerance induction?
SUBLINGUAL IMMUNOTHERAPY: What is the role in mucosal tolerance induction? Isil B.Barlan,MD Nerin N.Bahceciler,MD Division of Pediatric Allergy / Immunology Marmara University, Faculty of Medicine Istanbul,Turkey
More informationMP Diagnostic Tests for Allergic and Immune Deficiency Diseases of Uncertain Efficacy
Medical Policy MP 2.04.500 Diagnostic Tests for Allergic and Immune Deficiency Diseases of Uncertain Efficacy Last Review: 04/30/2018 Effective Date: 04/30/2018 Section: Medicine Related Policies 9.01.502
More informationBackground: Anaphylactic shock causes an estimated 1,500 deaths every year in the
Alina Lorant and Kenneth Smith ABSTRACT Background: Anaphylactic shock causes an estimated 1,500 deaths every year in the United States alone and millions suffer from allergic rhinitis. Despite the documentation
More informationMouse Total IgA Antibody Detection Kit
Mouse Total IgA Antibody Detection Kit Catalog # 3019 For Research Use Only - Not Human or Therapeutic Use INTRODUCTION The total IgA levels in specimens are often determined in mouse disease models involving
More informationSkin prick testing: Guidelines for GPs
INDEX Summary Offered testing but where Allergens precautions are taken Skin prick testing Other concerns Caution Skin testing is not useful in these following conditions When skin testing is uninterpretable
More informationAilléirge Péidiatraiceach. Pediatric Allergy 3/9/2018. Disclosures & Conflicts Of Interest
Ailléirge Péidiatraiceach Michael Zacharisen, M.D. Allergy/Immunology Pediatric Allergy Michael Zacharisen, M.D. Allergy/Immunology Disclosures & Conflicts Of Interest Green Bay Packer fan I drive a Jeep
More informationUNIVERSITY OF ZAGREB SCHOOL OF MEDICINE. Plan of the course. Basics of Pediatric Allergy. Academic year 2015/2016. Mirjana Turkalj
UNIVERSITY OF ZAGREB SCHOOL OF MEDICINE Plan of the course Basics of Pediatric Allergy Academic year 2015/2016 I. COURSE AIMS COURSE OUTLINE The specialty of allergy involves the management of a wide range
More informationLinda Cross 0. Development and Treatments. of Allergies. Linda Cross. BIOL 1503, section 2
Linda Cross 0 Development and Treatments of Allergies Linda Cross BIOL 1503, section 2 Linda Cross 1 Allergies have been used to describe various ailments in the past, but have come to describe a specific
More informationNew Targets for Immune Modulation in Asthma Willem van de Veen, PhD Mübeccel Akdis, MD, PhD *
Current Treatment Options in Allergy (2014) 1:171 185 DOI 10.1007/s40521-014-0011-3 Asthma (M Jutel, Section Editor) New Targets for Immune Modulation in Asthma Willem van de Veen, PhD Mübeccel Akdis,
More informationAssessing the Relative Risks of Subcutaneous and Sublingual Allergen Immunotherapy
Assessing the Relative Risks of Subcutaneous and Sublingual Allergen Immunotherapy Tolly Epstein, MD, MS Assistant Professor of Clinical Medicine Division of Immunology, Allergy & Rheumatology University
More informationMohamed Shamji, PhD. CS. FAAAAI
Short Course treatment of Subcutaneous Peptide Hydrolysate from Lolium Perenne - gp-asit+ TM - suppresses Basophil Responses and induces IgGassociated Blocking Antibodies: A RDPCT Mohamed Shamji, PhD.
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationAntibody responses to bee melittin (Api m 4) and hornet antigen 5 (Dol m 5) in mice treated with the dominant T-cell epitope peptides
Antibody responses to bee melittin (Api m 4) and hornet antigen 5 (Dol m 5) in mice treated with the dominant T-cell epitope peptides Te Piao King, PhD, Gang Lu, MD, and Harvey Agosto, BA New York, N.
More information4/28/2016. Host Defenses. Unit 8 Microorganisms & The Immune System. Types of Innate Defenses. Defensive Cells Leukocytes
Host Defenses Unit 8 Microorganisms & The Immune System CH 16-18 Host defenses that produce resistance can be either innate or adaptive: Innate: those that protect against any type of invading agent Adaptive:
More informationGrass pollen immunotherapy induces Foxp3 expressing CD4 + CD25 + cells. in the nasal mucosa. Suzana Radulovic MD, Mikila R Jacobson PhD,
Radulovic 1 1 2 3 Grass pollen immunotherapy induces Foxp3 expressing CD4 + CD25 + cells in the nasal mucosa 4 5 6 7 Suzana Radulovic MD, Mikila R Jacobson PhD, Stephen R Durham MD, Kayhan T Nouri-Aria
More informationAllergy Testing and Practical Mitigation Measures
Allergy Testing and Practical Mitigation Measures Carol T Cady, MD, PhD Big Sky Pulmonary Conference March 24th, 2012 Overview of Allergies and Mitigation The human component The environmental component
More informationPublic Assessment Report. Scientific discussion. Grazax / Grazura SE/H/612/MR / SE/H/613/MR
Public Assessment Report Scientific discussion Grazax / Grazura allergen extract from Phleum pratense SE/H/612/MR / SE/H/613/MR This module reflects the scientific discussion for the approval of Grazax
More informationAllergen Immunotherapy
Allergen Immunotherapy April 8, 2017 AAOM Annual Conference Richard F. Lockey, M.D. Distinguished University Health Professor Professor of Medicine, Pediatrics and Public Health Director, Division of Allergy
More informationDr ARIF AHMED M.D.(Paed.), D.Ch., M.D.(USA), European Board (EACCI) Certified in Allergy & Immunology
Case Based Approach to Allergic Unified Airway Diseases Dr ARIF AHMED M.D.(Paed.), D.Ch., M.D.(USA), European Board (EACCI) Certified in Allergy & Immunology Recent Advances in Pediatrics 23: Hot Topics
More informationG. Zadoyan, K. Shah-Hosseini, A. Astvatsourov, L. Sohlich, E.M. Kasche, M.H. Shamji, S.R. Durham, S. Pirotton, T. Legon, R. Mösges
A prospective, randomized, double-blind placebo-controlled multi-centre dose-finding study of 3 different regimens of gpasit+ administered subcutaneously to adult patients with grass pollen-induced allergic
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 GRAZAX 75 000 SQ-T, oral lyophilisate B/30 (CIP: 378 011-6) B/100 (CIP code: 378 012-2) B/90 (CIP code:
More informationCorporate Medical Policy Allergy Immunotherapy (Desensitization)
Corporate Medical Policy Allergy Immunotherapy (Desensitization) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: allergy_immunotherapy 7/1979 11/2017 11/2018 11/2017 Description
More informationIs there an allergy epidemic and what are the possible causes?
Is there an allergy epidemic and what are the possible causes? Professor Michael Gold Department of Allergy and Immunology Women s and Children s Health Network Discipline of Paediatrics University of
More informationEpicutaneous Immunotherapy for Aeroallergen and Food Allergy
Current Treatment Options in Allergy (2014) 1:68 78 DOI 10.1007/s40521-013-0003-8 Specific Immunotherapy (L Cox, Section Editor) Epicutaneous Immunotherapy for Aeroallergen and Food Allergy Gabriela Senti,
More informationTopics. Humoral Immune Response Part II Accessory cells Fc Receptors Opsonization and killing mechanisms of phagocytes NK, mast, eosynophils
Topics Humoral Immune Response Part II Accessory cells Fc Receptors Opsonization and killing mechanisms of phagocytes NK, mast, eosynophils Immune regulation Idiotypic network 2/15/2005 MICR 415 / 515
More informationRecognition & Management of Anaphylaxis in the Community. S. Shahzad Mustafa, MD, FAAAAI
Recognition & Management of Anaphylaxis in the Community S. Shahzad Mustafa, MD, FAAAAI Disclosures None Outline Define anaphylaxis Pathophysiology Common causes Recognition and Management Definition Acute,
More informationAllergic Disorders. Allergic Disorders. IgE-dependent Release of Inflammatory Mediators. TH1/TH2 Paradigm
Allergic Disorders Anne-Marie Irani, MD Virginia Commonwealth University Allergic Disorders IgE-mediated immune reactions Clinical entities include: asthma allergic rhinitis atopic dermatitis urticaria
More informationAllergic Disorders. Allergic Disorders. IgE-dependent Release of Inflammatory Mediators. TH1/TH2 Paradigm
Allergic Disorders Anne-Marie Irani, MD Virginia Commonwealth University Allergic Disorders IgE-mediated immune reactions Clinical entities include: asthma allergic rhinitis atopic dermatitis urticaria
More informationImmunotherapy for Food Allergy: Is it Ready for Primetime?
Immunotherapy for Food Allergy: Is it Ready for Primetime? Bruce J. Lanser, MD Assistant Professor of Pediatrics Director, National Jewish Health Pediatric Food Allergy Center Associate Director, Pediatric
More informationAbstract and Introduction
www.medscape.com From Current Opinion in Allergy and Clinical Immunology Clinical Outcome Measures of Specific Immunotherapy Oliver Pfaar; Clemens Anders; Ludger Klimek Published: 07/20/2009 Abstract and
More informationAllergy Immunotherapy in the Primary Care Setting
Allergy Immunotherapy in the Primary Care Setting New York State College Health Association 2008 COMBINED ANNUAL MEETING October 2008 Mary Madsen RN BC University of Rochester Issues in Primary Care Practice
More informationThe mouse cholera toxin model for evaluation of allergenicity
The mouse cholera toxin model for evaluation of allergenicity Joost Smit, ILSI 2012 Of mice and men.(mestas, J Immunol 2004; 172:2731) Mouse Human Neutrophils in blood 10-25% 50-70% Lymphocytes in blood
More informationThe Current Status of Sublingual Immunotherapy
The Current Status of Sublingual Immunotherapy Harold S. Nelson, MD Professor of Medicine National Jewish Health and University of Colorado Denver School of Medicine Denver, Colorado Disclosure: Harold
More informationHypersensitivity Reactions
Color code: Important in red Extra in blue Hypersensitivity Reactions For team error adjustments, click here Objectives To know that hypersensitivity reactions are over and excessive immune responses that
More informationChinese Guideline on allergen immunotherapy for allergic rhinitis
Guideline Chinese Guideline on allergen immunotherapy for allergic rhinitis Yixiao Bao 1 *, Jianjun Chen 2 *, Lei Cheng 3,4 *, Yinshi Guo 5 *, Suling Hong 6 *, Weijia Kong 2 *, He Lai 7 *, Houyong Li 8
More information